What should a first psoriasis appointment cover?
More than a look at your skin. A full assessment covers the skin itself, your nails, any high-impact site, how it affects your day-to-day life, and any joint concerns. Evidence
Why this item matters
- Sources cited, not yet graded
NICE guidance assesses psoriasis across five areas at once: the skin, the nails, high-impact sites, the effect on daily life, and any joint concerns. None of the five stands in for the others.
Check before moving on
- Depends on you
NICE is UK guidance and sets no US coverage or scheduling rule. It does not say all five areas have to be covered in one visit, or how a specific office splits that work across visits.
Questions for your dermatologist
Which of those five areas did we cover today, and which are you leaving open for a follow-up?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Why might the visit point you to a rheumatologist instead of a treatment start?
If your exam turns up signs that could be joint disease, being sent for a closer look is a step in the plan, not a stall. Psoriatic arthritis has no single test, so ruling it in or out can take more than one appointment. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
NIAMS describes the diagnostic process as a symptom history and physical exam, plus blood tests to rule out other conditions. It adds imaging, such as X-rays, ultrasound or MRI, when needed. It states there is no single definitive test. The AAD names specific warning signs beyond ordinary joint pain, such as a swollen finger or toe and morning stiffness lasting 30 to 45 minutes or more. Others are pitted or lifting nails, and pain low in the back or at the heel. The AAD states early treatment helps prevent joint damage.
Check before moving on
- Depends on you
Neither source says a rheumatologist referral is a required diagnostic step, only that rheumatologists are among the specialists who treat the condition. How quickly a referral happens depends on your plan and local access, not on either source. A symptom list or exam alone does not diagnose psoriatic arthritis.
Questions for your dermatologist
What specifically made you want another opinion?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If a swollen joint, long morning stiffness, nail changes, or low-back pain shows up while I wait, should I come back sooner?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which of my own symptoms should I track before that appointment - joint pain, swelling, or stiffness?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can you bring to make today count for more?
A dated record: written notes on your symptoms, plus a photo series. More of the visit can go toward a plan, instead of reconstructing the last six weeks from memory. Evidence Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The National Psoriasis Foundation says to bring a symptom record on paper or a phone, describing symptoms clearly and noting changes in severity and in the areas affected. Its flare guide offers a worksheet for daily symptoms. A comparable photo series needs a plain background, a level camera, and the same light and position each time. It needs the same distance of about three to five feet, the same body areas each time, and a date on every picture.
Check before moving on
- Depends on you
The photo technique comes from a page written for vitiligo, a different condition; only the camera method is carried over here. Neither NPF page gives a percentage or timeline for how much a record changes a visit. A record is not a diagnosis or a severity score on its own.
Questions for your dermatologist
Which part of what I brought changed today’s plan, and what goes in my file for next time?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What decides whether a topical is enough, or something stronger is on the table today?
A severity read, not just how it looks to you. That means the share of skin involved, whether it sits on a site that counts on its own, and whether topical treatment has already been tried and failed. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The International Psoriasis Council replaced the mild-moderate-severe scale with two classes: a candidate for topical therapy, or a candidate for systemic therapy. Any one of three criteria is enough for the systemic class. The first is 10 per cent or more of the body surface. The second is a high-impact site such as the face, palms, soles, genitals, scalp or nails. The third is two four-week courses of topical treatment in a row that did not reach clear or almost clear skin. The National Psoriasis Foundation adopted a matching two-class definition, naming the same high-impact sites.
Check before moving on
- Depends on you
Neither body sets a health plan’s rule. Neither names a prior authorization step, an appeal route or a deadline, and neither says how much topical treatment a given plan will count as already tried.
Questions for your dermatologist
Based on today, which of the two classes am I in, and will that go in my notes in those words?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports telling a dermatologist about a finger or toe that swells all the way along (a "sausage digit"). Also supports naming swollen, tender joints, and morning stiffness that lasts 30 to 45 minutes or longer and eases with movement. Also supports naming pitted or lifting nails, and low-back or heel pain, including swelling above the heel. Supports that for most people psoriatic arthritis develops years after psoriasis. Supports that psoriatic arthritis destroys the joints in some people, and that early treatment helps prevent this.
What it does not support
Does not give a percentage or fraction of people with psoriasis who go on to develop psoriatic arthritis. This page displays no separate revision date; the date recorded here matches the same AAD psoriatic-arthritis series’ treatment page, checked the same day. Does not diagnose psoriatic arthritis from a symptom list alone.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- International Psoriasis CouncilGuideline · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The International Psoriasis Council names its corporate members on its own site (psoriasiscouncil.org/about/corporate-members/, checked 2026-09-11). The top tier names AbbVie, Johnson & Johnson, Eli Lilly, Novartis and Takeda. LEO Pharma, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis and Oruka sit below them. Those firms make the drugs this severity rule opens the door to. A wider rule on who qualifies is a wider market for them. The page says nothing about how that money relates to IPC independence.
What this source supports
Supports that IPC dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Supports that any one of three criteria is enough to be a candidate for systemic therapy. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. IPC names those sites as the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy. Supports that IPC defines that failure in writing. It is not reaching clear or almost-clear skin after two four-week courses in a row. IPC gives clear or almost-clear as 1% or less body surface, with a physician global assessment of 0 or 1. Supports the source paper. It is Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020 Jan;82(1):117-122. Supports that IPC's own June 2025 teaching deck lists payers among the groups it set out to move. That deck also names refusal to pay as a result of the older scale.
What it does not support
Does not set any health plan's coverage rule. This is a professional-society consensus. It is not a regulation and not a plan document. Does not say which systemic treatment follows once a person meets a criterion. It sets no dose, no frequency and no schedule. Does not give the number of experts who voted, the response rate, or their conflict-of-interest disclosures. IPC's own June 2025 deck states the body-surface threshold two ways. Its criteria summary says 10% or more. The slide expanding that criterion says above 10%. Does not establish that a given reader meets a criterion. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that NPF adopted a two-class definition. Mild psoriasis can be managed with topical therapies. Moderate-to-severe psoriasis makes a person a candidate for advanced therapies. Supports its statement that "Moderate-to-severe psoriasis is not determined solely by body surface area (BSA) involvement of 10%." Supports that psoriasis on a high-impact site counts too. NPF gives those sites as the face, scalp, hands, feet, nails or genitals. It says such patients "should also be considered as having 'moderate-to-severe' disease". Supports that the same holds for people who cannot get adequate control from topical therapies. Supports its statement that "People with psoriasis should never be denied advanced care because of outdated measures."
What it does not support
Does not set any health plan's coverage rule and does not bind a payer. Does not name prior authorization, appeals or denial steps. Gives no appeal deadline and no appeal process. Does not say how much topical treatment counts as inadequate control, or over what period. Does not establish that a given reader is a candidate for a named therapy. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that tracking symptoms and common triggers over time can help a person figure out their own specific triggers. Supports naming stress, alcohol, and diet as examples of common triggers to watch for. Supports naming discolored skin patches and itching as psoriasis symptoms, and joint swelling and fatigue as psoriatic arthritis symptoms, to watch for. Supports using a worksheet to record daily symptoms and their severity, and sharing that worksheet with a health care provider.
What it does not support
Does not give a percentage or timeline for how much tracking changes any one outcome. Does not name every possible trigger - stress, alcohol, and diet are examples, not a complete list. Does not measure whether tracking itself helps or burdens a given person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- MyVitiligoTeamPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a solid-colored background for a comparable photo series. Black, green, or dark blue are named as ones that help skin stand out. Supports using the same artificial light in the same position each time, rather than sunlight. Supports holding the camera straight rather than tilted. Supports a distance of about 3 to 5 feet, held the same every time. Supports photographing a fixed list of body areas the same way every time. Supports using a ruler for scale and tagging each photo with its date.
What it does not support
Written and reviewed for tracking vitiligo, a different condition, not for psoriasis. Only the general camera technique - background, lighting, angle, distance, and framing - is used here; nothing about vitiligo itself is carried over. Does not establish that photo tracking changes any psoriasis outcome.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing joint, tendon, swelling, stiffness and nail concerns to a clinician because diagnosis uses clinical assessment and may require further evaluation.
What it does not support
It is not an online screening result and cannot diagnose psoriatic arthritis from a checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.